Radiation zaps lingering brain tumors in lung cancer patients
NCT ID NCT06020066
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether adding precise radiation (stereotactic radiosurgery) to standard drug therapy can better control brain metastases in people with non-small cell lung cancer. Participants have brain tumors that remain after 3-6 months of a targeted drug. The goal is to see if the combination delays cancer progression and improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
stereotactic radiotherapy (precise radiation beams)
What this could lead to
If successful, this approach could help control brain metastases in lung cancer patients, potentially delaying disease progression and improving survival without needing stronger drugs.
What could go wrong
This is a Phase 2 trial with 202 participants, so results are still preliminary. The added radiation may cause side effects like brain swelling or fatigue, and it may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200030, China